Edition:
United States

Biosynex SA (ALBIO.PA)

ALBIO.PA on Paris Stock Exchange

4.36EUR
5:36am EDT
Change (% chg)

€0.16 (+3.81%)
Prev Close
€4.20
Open
€4.25
Day's High
€4.36
Day's Low
€4.25
Volume
524
Avg. Vol
9,031
52-wk High
€4.45
52-wk Low
€2.11

Latest Key Developments (Source: Significant Developments)

Biosynex launches capital increase for maximum amount of 3.39 million euros
Tuesday, 29 Nov 2016 12:00pm EST 

Biosynex SA : Launches a capital increase guaranteed by the founding shareholders with preferential subscription rights for a maximum amount of 3.39 million euros ($3.60 million) . Subscription from December 6 to December 14, 2016 . 22 DPS giving right to subscribe for 5 new shares .Unit price of 2.1 euros.  Full Article

Biosynex H1 revenue up at 13.3 million euros
Thursday, 28 Jul 2016 01:00am EDT 

Biosynex SA :H1 revenue 13.3 million euros ($14.72 million) versus 10.7 million euros year ago.  Full Article

Biosynex awarded 1 mln euro innovation loan by Bpifrance
Monday, 18 Jul 2016 01:00am EDT 

Biosynex SA : Awarded European Investment Fund innovation loan by Bpifrance to finance deployment of its product .Loan is for 1 million euros ($1.11 million).  Full Article

Biosynex finalizes 2 acquisitions
Tuesday, 5 Jul 2016 02:10am EDT 

Biosynex SA : Finalizes 2 acquisitions which should generate additional annual revenue of 12 million euros ($13.4 million) .From 2017, this double acquisition should generate a growth of 75 pct in group revenue.  Full Article

Biosynex wins agreement with DRC for order of 10 CellsCheck
Tuesday, 24 May 2016 12:03pm EDT 

Biosynex SA : Announces agreement with Democratic Republic of Congo . Agreement for order of 10 CellsCheck .This first order will allow to equip some of the 26 Congolese provinces before the end of 2017.  Full Article

Biosynex to acquire Fumouze Diagnostics
Wednesday, 18 May 2016 02:07am EDT 

Biosynex SA :Signing of a binding agreement to acquire Fumouze Diagnostics.  Full Article

Biosynex obtains CE mark for Exacto Pro Test HIV
Tuesday, 16 Feb 2016 02:00am EST 

Biosynex SA:Obtains CE mark for rapid serological test new generation of infection by HIV 1 and 2 responsible for AIDS (Exacto Pro Test HIV).  Full Article

Project of simplified merger of Alldiag by Biosynex
Wednesday, 2 Dec 2015 12:03pm EST 

Biosynex SA:Project of simplified merger of Alldiag by Biosynex.Operation will not result in a capital increase and will not change Biosynex statuts.  Full Article

Biosynex launches capital increase to a maximum of 1.96 million euros and gives 2015 guidance
Sunday, 18 Oct 2015 08:00pm EDT 

Biosynex SA:Launches capital increase with preferential subscription rights to a maximum of 1.96 million euros.Capital increase with preferential subscription rights for issuance of 713,999 shares at unit price of 2.75 euros.Expects 2015 revenue of 21 million euros and EBE of 1.4 million euros.  Full Article

Biosynex says higher diagnostic accuracy of 'Amnioquick DUO+'
Monday, 12 Oct 2015 11:48am EDT 

Biosynex SA:Announces new success for premature rupture of fetal membranes test 'Amnioquick DUO+.Clinical study on 185 patients allowed the evaluators to put forward a higher diagnostic accuracy of 'Amnioquick DUO+.  Full Article

More From Around the Web

BRIEF-Biosynex FY 2016 revenue rises to 27.0 million euros

* FY 2016 revenue 27.0 million euros ($29.01 million) versus 20.1 million euros a year ago Source text for Eikon: Further company coverage: ($1 = 0.9308 euros) (Gdynia Newsroom)